| |
|
|
|
Marriott Long Wharf Hotel, 296 State Street, Boston, MA 02109, USA
August 11-14, 2014
ImVacS, The Immunotherapies and Vaccine Summit, brings together a global audience of vaccine researchers and developers of cancer immunotherapies for four focused meetings that explore the frontiers of immunology as the basis for patient treatment.
Part 1 of the 9th annual "Novel Vaccines" meeting addresses "Adjuvants, TLRs and DNA Vaccines," while Part 2 explores "Emerging Vaccine Technologies." The 2nd annual "Immunomodulatory Therapeutic Antibodies for Cancer" meeting examines developments in the models and tools used in developing these emerging drug products, while the inaugural "Combination Cancer Immunotherapy" meeting focuses on the application of these antibody programs in combination with other treatment modalities. Target Discovery for T Cell Therapy Symposium will bring together leading academic and industry researchers to discuss how to find and validate suitable targets and antigens for t cell therapies.
|
|
|
|
|
|
|
|
Organized by:
|
|
Cambridge Healthtech Institute (CHI) |
|
|
Invited Speakers:
|
|
Keynote Speakers: - Norman W. Baylor, Ph.D., President and CEO, Biologics Consulting Group, Inc.
- Bolyn Hubby, Ph.D., Senior Director, Head, Vaccine and Phage R&D, Synthetic Genomics Vaccines, Inc.
- Michael A. Postow, M.D., Assistant Attending Physician, Melanoma and Immunotherapeutics Service, Memorial Sloan-Kettering Cancer Center
- Omid Hamid, M.D., Director, Melanoma Center, Angeles Clinic and Research Institute
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
---
|
|
|
|
|
|
|
|
Registration:
|
|
Register Now
|
|
|
E-mail:
|
|
kwaterman@healthtech.com
|
|
|
|
|
|
|
|
|